Airway Alkalinization and Repurposing Tromethamine as a Therapeutic Approach in Cystic Fibrosis
气道碱化和重新利用氨丁三醇作为囊性纤维化的治疗方法
基本信息
- 批准号:9289053
- 负责人:
- 金额:$ 107.03万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2017
- 资助国家:美国
- 起止时间:2017-04-10 至 2022-03-31
- 项目状态:已结题
- 来源:
- 关键词:AffectAgeAlkalinizationAnimalsBicarbonatesBirthBuffersChronicClinicalClinical ResearchCystic FibrosisCystic Fibrosis Transmembrane Conductance RegulatorDataDefectDevelopmentDiseaseDuct (organ) structureEarly InterventionFDA approvedFailureFamily suidaeGenesGlandGoalsHereditary DiseaseHost DefenseHost Defense MechanismHourHumanImpairmentInfectionInflammationKnowledgeLeadLifeLungLung diseasesMediatingMetabolic acidosisMucociliary ClearanceMucous body substanceMutationNewborn InfantPathogenesisPharmaceutical PreparationsPositioning AttributePropertyPublishingPulmonary Cystic FibrosisRecurrenceRespiratory FailureRheologyTestingTherapeuticTherapeutic InterventionTimeTranslatingTris-ATromethamineViscosityWorkaerosolizedairway surface liquidalkalinityantimicrobialbaseclinical developmentcystic fibrosis airwayearly cystic fibrosisimprovedinfancykillingsnew therapeutic targetnovel therapeutic interventionnovel therapeuticspre-clinicalpreventrestorationscreeningtherapeutic developmenttherapeutic target
项目摘要
PROJECT SUMMARY
Despite the development of new therapies, cystic fibrosis (CF) remains a life-shortening disease. Airway infec-
tion and inflammation begin during infancy and lead to respiratory failure. Thus, early interventions aimed at
correcting the initial host defense defects and preventing/reducing infection could dramatically improve the
course of CF lung disease. It is well known that mutations in the gene encoding CFTR, a HCO – and Cl– con-
3
ducting channel, cause CF. Yet, the origins of CF lung disease have remained less well understood. We dis-
covered that loss of CFTR impairs two important airway host defense mechanisms. a) Reduced activity of air-
way surface liquid (ASL) antimicrobials. b) More viscous mucus that also has abnormal properties, impairing
its ability to detach from submucosal gland ducts, thus hindering mucociliary transport (MCT). In both cases,
loss of CFTR-mediated HCO3– secretion and an abnormally acidic pH are key factors. Our long-term goal is to
develop novel therapeutics that target primary host defense defects due to loss of CFTR function. The overall
objective of this proposal is to determine if airway alkalinization, with a repurposed drug, can prevent or allevi-
ate the development of CF airway disease. Our hypothesis is that airway alkalinization with tromethamine
(THAM, an FDA-approved alkalinizing agent in human clinical use for metabolic acidosis), will restore airway
host defenses in CF and prevent/alleviate the development of CF airway disease. We found in humans and
pigs that aerosolized THAM, a tris-based, non-bicarbonate buffer, causes a sustained increase in ASL pH and
the effect lasts for hours, in contrast to a much shorter duration with NaHCO3. THAM enhanced ASL bacterial
killing and decreased mucus viscosity. We test the following Specific Aims: Aim 1. Does aerosolized THAM
produce a prolonged increase in ASL pH and enhance antimicrobial activity in pigs and humans? Based upon
our published and unpublished data, our working hypothesis is that aerosolized THAM will increase ASL pH
and restore ASL antimicrobial properties, in humans and pigs with CF. Aim 2. Will airway alkalinization im-
prove MCT? From our earlier studies, we postulate that airway alkalinization with THAM will reverse MCT de-
fects in CF, thereby enhancing MCT in CF. Aim 3. Does airway alkalinization alleviate or prevent early airway
disease in CF pigs? Our published and preliminary data show that CF pigs already have airway host defense
defects present at birth and develop airway disease within 3 weeks of age. Thus, we hypothesize that, in CF
pigs, long-term restoration of ASL pH with THAM will improve airway host defense and lessen or prevent early
airway disease in CF pigs. We are uniquely positioned to translate our recent discoveries on the pathogenesis
of CF lung disease into a therapeutic intervention. These results, from both human and preclinical animal stud-
ies, will be transformative for CF and likely other airway diseases. They will have an important positive impact
on accelerating clinical development of THAM and other new therapeutic interventions and endpoints for early
CF, a critically important time point in the era of universal newborn CF screening.
项目摘要
尽管开发了新的治疗方法,囊性纤维化(CF)仍然是一种缩短寿命的疾病。呼吸道感染-
炎症开始于婴儿期并导致呼吸衰竭。因此,早期干预的目的是
纠正最初的主机防御缺陷和预防/减少感染可以大大提高
CF肺病的病程。众所周知,编码CFTR的基因中的突变,
3
导管通道,导致CF。然而,CF肺病的起源仍然不太清楚。我们不-
报道了CFTR的丢失损害了两种重要的气道宿主防御机制。(a)空气活动减少-
方式表面液体(ASL)抗菌剂。B)更粘稠的粘液,也有异常的性质,损害
其与粘膜下腺管分离的能力,从而阻碍粘膜纤毛转运(MCT)。在这两种情况下,
CFTR介导的HCO 3分泌的丧失和异常酸性pH是关键因素。我们的长期目标是
开发靶向由于CFTR功能丧失导致的原发性宿主防御缺陷的新疗法。整体
本提案的目的是确定气道碱化,与一个重新利用的药物,可以预防或减轻,
导致CF气道疾病的发展。我们的假设是氨丁三醇导致气道碱性化
(THAM是FDA批准的用于人类临床代谢性酸中毒的碱化剂),
CF中的宿主防御和预防/减轻CF气道疾病的发展。我们在人类身上发现的,
雾化THAM(一种基于三羟甲基氨基甲烷的非碳酸氢盐缓冲剂)的猪,导致ASL pH值持续升高,
与NaHCO 3的短得多的持续时间相比,该效果持续数小时。THAM增强ASL细菌
杀死并降低粘液粘度。我们测试以下具体目标:目标1。雾化的THAM
在猪和人类中产生ASL pH值的长期增加并增强抗菌活性?基于
根据我们已发表和未发表的数据,我们的工作假设是,雾化THAM将增加ASL pH值,
并恢复ASL的抗菌性能,在人类和猪CF。目标二。气道碱化是否会影响-
证明MCT?从我们早期的研究中,我们假设气道碱化THAM将逆转MCT脱-
在CF中的作用,从而增强CF中的MCT。目标3。气道碱化是否减轻或预防早期气道
CF猪的疾病?我们已发表的和初步的数据表明,CF猪已经有气道宿主防御
出生时就存在缺陷,并在3周龄内发展为呼吸道疾病。因此,我们假设,在CF
猪,长期恢复ASL pH与THAM将改善气道宿主防御和减少或防止早期
CF猪的呼吸道疾病。我们处于独特的地位,可以将我们最近在发病机制方面的发现
转化为治疗干预。这些结果来自人类和临床前动物研究,
即,将改变CF和可能的其他气道疾病。它们将产生重要的积极影响
加速THAM和其他新的治疗干预措施和终点的临床开发,
CF是新生儿CF筛查普及时代的一个至关重要的时间点。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
DAVID A STOLTZ其他文献
FATAL LUNG INJURY SECONDARY TO TRIMETHOPRIM-SULFAMETHOXAZOLE
- DOI:
10.1016/j.chest.2023.07.1615 - 发表时间:
2023-10-01 - 期刊:
- 影响因子:
- 作者:
HALEY PYSICK;DAVID A STOLTZ - 通讯作者:
DAVID A STOLTZ
DAVID A STOLTZ的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('DAVID A STOLTZ', 18)}}的其他基金
Climate Change and Lung Health Training Program
气候变化与肺部健康培训计划
- 批准号:
10556149 - 财政年份:2023
- 资助金额:
$ 107.03万 - 项目类别:
Testing the Contributions of Airway Submucosal Glands and Surface Epithelia to Lung Health
测试气道粘膜下腺和表面上皮对肺部健康的贡献
- 批准号:
10597111 - 财政年份:2022
- 资助金额:
$ 107.03万 - 项目类别:
Airway Alkalinization and Repurposing Tromethamine as a Therapeutic Approach in Cystic Fibrosis
气道碱化和重新利用氨丁三醇作为囊性纤维化的治疗方法
- 批准号:
10155587 - 财政年份:2017
- 资助金额:
$ 107.03万 - 项目类别:
Airway Alkalinization and Repurposing Tromethamine as a Therapeutic Approach in Cystic Fibrosis
气道碱化和重新利用氨丁三醇作为囊性纤维化的治疗方法
- 批准号:
9918957 - 财政年份:2017
- 资助金额:
$ 107.03万 - 项目类别:
Paraoxonase-2 S311C Polymorphism Alters Glycosylation and Lactonase Activity
Paraoxonase-2 S311C 多态性改变糖基化和内酯酶活性
- 批准号:
8110743 - 财政年份:2010
- 资助金额:
$ 107.03万 - 项目类别:
相似国自然基金
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
- 批准号:JCZRQN202500010
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
- 批准号:2025JJ70209
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
- 批准号:
- 批准年份:2024
- 资助金额:0 万元
- 项目类别:面上项目
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
- 批准号:2023JJ50274
- 批准年份:2023
- 资助金额:0.0 万元
- 项目类别:省市级项目
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
- 批准号:
- 批准年份:2022
- 资助金额:33 万元
- 项目类别:地区科学基金项目
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
- 批准号:
- 批准年份:2022
- 资助金额:52 万元
- 项目类别:面上项目
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
- 批准号:n/a
- 批准年份:2022
- 资助金额:10.0 万元
- 项目类别:省市级项目
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
- 批准号:81973577
- 批准年份:2019
- 资助金额:55.0 万元
- 项目类别:面上项目
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
- 批准号:81602908
- 批准年份:2016
- 资助金额:18.0 万元
- 项目类别:青年科学基金项目
高血糖激活滑膜AGE-RAGE-PKC轴致骨关节炎易感的机制研究
- 批准号:81501928
- 批准年份:2015
- 资助金额:18.0 万元
- 项目类别:青年科学基金项目
相似海外基金
Collaborative Research: Resolving the LGM ventilation age conundrum: New radiocarbon records from high sedimentation rate sites in the deep western Pacific
合作研究:解决LGM通风年龄难题:西太平洋深部高沉降率地点的新放射性碳记录
- 批准号:
2341426 - 财政年份:2024
- 资助金额:
$ 107.03万 - 项目类别:
Continuing Grant
Collaborative Research: Resolving the LGM ventilation age conundrum: New radiocarbon records from high sedimentation rate sites in the deep western Pacific
合作研究:解决LGM通风年龄难题:西太平洋深部高沉降率地点的新放射性碳记录
- 批准号:
2341424 - 财政年份:2024
- 资助金额:
$ 107.03万 - 项目类别:
Continuing Grant
PROTEMO: Emotional Dynamics Of Protective Policies In An Age Of Insecurity
PROTEMO:不安全时代保护政策的情绪动态
- 批准号:
10108433 - 财政年份:2024
- 资助金额:
$ 107.03万 - 项目类别:
EU-Funded
The role of dietary and blood proteins in the prevention and development of major age-related diseases
膳食和血液蛋白在预防和发展主要与年龄相关的疾病中的作用
- 批准号:
MR/X032809/1 - 财政年份:2024
- 资助金额:
$ 107.03万 - 项目类别:
Fellowship
Atomic Anxiety in the New Nuclear Age: How Can Arms Control and Disarmament Reduce the Risk of Nuclear War?
新核时代的原子焦虑:军控与裁军如何降低核战争风险?
- 批准号:
MR/X034690/1 - 财政年份:2024
- 资助金额:
$ 107.03万 - 项目类别:
Fellowship
Walkability and health-related quality of life in Age-Friendly Cities (AFCs) across Japan and the Asia-Pacific
日本和亚太地区老年友好城市 (AFC) 的步行适宜性和与健康相关的生活质量
- 批准号:
24K13490 - 财政年份:2024
- 资助金额:
$ 107.03万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Discovering the (R)Evolution of EurAsian Steppe Metallurgy: Social and environmental impact of the Bronze Age steppes metal-driven economy
发现欧亚草原冶金的(R)演变:青铜时代草原金属驱动型经济的社会和环境影响
- 批准号:
EP/Z00022X/1 - 财政年份:2024
- 资助金额:
$ 107.03万 - 项目类别:
Research Grant
ICF: Neutrophils and cellular senescence: A vicious circle promoting age-related disease.
ICF:中性粒细胞和细胞衰老:促进与年龄相关疾病的恶性循环。
- 批准号:
MR/Y003365/1 - 财政年份:2024
- 资助金额:
$ 107.03万 - 项目类别:
Research Grant
Doctoral Dissertation Research: Effects of age of acquisition in emerging sign languages
博士论文研究:新兴手语习得年龄的影响
- 批准号:
2335955 - 财政年份:2024
- 资助金额:
$ 107.03万 - 项目类别:
Standard Grant
Shaping Competition in the Digital Age (SCiDA) - Principles, tools and institutions of digital regulation in the UK, Germany and the EU
塑造数字时代的竞争 (SCiDA) - 英国、德国和欧盟的数字监管原则、工具和机构
- 批准号:
AH/Y007549/1 - 财政年份:2024
- 资助金额:
$ 107.03万 - 项目类别:
Research Grant